Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis.
Explore this paper's citation graph
Summary
In a small randomized controlled trial, a 12-month course of enoxaparin was safe and effective in preventing PVT in patients with cirrhosis and a Child-Pugh score of 7-10 and to improve survival.
- Type
- article
- Published
- 2012-11-01
- Cited by
- 717
- References
- 51
- Access
- Open access
- OpenAlex
- https://openalex.org/W1993340951
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:206226642
Keywords
Medicine, Decompensation, Portal vein thrombosis, Cirrhosis, Enoxaparin sodium
References
- Protein C and D‐dimer are related to portal vein thrombosis in patients with liver cirrhosis
- Bacterial translocation from the gastrointestinal tract.
- Continuation of Low-Dose Aspirin Therapy in Peptic Ulcer Bleeding
- Portal vein thrombosis in liver cirrhosis.
- CONSORT 2010 Statement: updated guidelines for reporting parallel group randomized trials
- Vascular liver disorders (II): portal vein thrombosis.
- THIS ARTICLE HAS BEEN RETRACTED: Haemodynamic derangement in human immunodeficiency virus‐infected patients with hepatitis C virus‐related cirrhosis: the role of bacterial translocation
- Combined liver vein and spleen pulp pressure measurements in patients with portal or splenic vein thrombosis
- Host Response to Translocated Microbial Products Predicts Outcomes of Patients with HBV or HCV infection
- Coagulation disorders in patients with cirrhosis and severe sepsis
- Portal vein thrombosis: a predictable milestone in cirrhosis?
- Systematic review: portal vein thrombosis in cirrhosis
- Coagulation status modulates murine hepatic fibrogenesis: implications for the development of novel therapies
- Hypercoagulation and thrombophilia in liver disease
- Safety and Efficacy of Anticoagulation Therapy With Low Molecular Weight Heparin for Portal Vein Thrombosis in Patients With Liver Cirrhosis
- Relation between lupus anticoagulant and splanchnic venous thrombosis in cirrhosis of the liver
- Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation
- Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease.
- Portal vein thrombosis, revisited.
- Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development.
Cited by
- Patient-reported outcomes of cirrhosis.
- Optimizing risk stratification in portal vein thrombosis after splenectomy and its primary prophylaxis with antithrombin III concentrates and danaparoid sodium in liver cirrhosis with portal hypertension.
- Review article: portal vein obstruction – epidemiology, pathogenesis, natural history, prognosis and treatment
- Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B
- Thrombelastography‐guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial
- Pleiotropic effects of statins in the diseases of the liver.
- Newer Oral Anticoagulants in the Treatment of Acute Portal Vein Thrombosis in Patients with and without Cirrhosis
- Coagulation, Microenvironment and Liver Fibrosis
- Site-specific risk factors for portal vein thrombosis and evaluation of anticoagulation efficacy in patients with cirrhosis
- Initial management of noncirrhotic splanchnic vein thrombosis: when is anticoagulation enough?
- Gerinnungsdiagnostik und -therapie bei Leberinsuffizienz
- Anticoagulant Therapy in Patients with Cirrhosis
- Optimal Management of Portal Vein Thrombosis in Patients with Liver Cirrhosis: a Review
- Hemostasis abnormalities in cirrhosis
- Portal vein thrombosis in patients with cirrhosis
- Portal vein thrombosis in liver cirrhosis.
- Effects of restoring portal flow with anticoagulation and partial splenorenal shunt embolization
- Thrombin generation measured as thrombin–antithrombin complexes predicts clinical outcomes in patients with cirrhosis
- Novel insights into the development of portal vein thrombosis in cirrhosis patients
- Routine coagulation assays underestimate levels of antithrombin‐dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis
Related papers
- ALBI and PALBI: Novel Scores for Outcome Prediction of Cirrhotic Outpatients Awaiting Liver Transplantation.
- Analysis of relationship between clinical stages of cirrhosis with platelet and blood coagulation function after chronic hepatitis B
- Sodium metabolic change in cirrhosis patients in decompensation
- [Complexities and challenges in the management of portal vein thrombosis in cirrhosis].
- Compensated liver cirrhosis: Natural course and disease-modifying strategies
- Self-management behaviors and influencing factors in patients with liver cirrhosis during decompensation period
- Liver cirrhosis.
- Cirrhosis of liver and portal vein thrombosis - a review article.
- Comparison of Branded Enoxaparin (Lovenox) and a Biosimilar Version of Enoxaparin (Fibrinox)